Drug Trial Radar · NCT04397263
A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Jun 10, 2020
Primary completion
Feb 29, 2024
Study completion Sep 12, 2025
Sponsor
- Lead sponsor
- Janssen Pharmaceutical K.K.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- May 21, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety of Guselkumab in participants with Crohn's disease.
Conditions
- Crohns Disease
Interventions
GuselkumabDrug
Guselkumab will be administered intravenously for the first 3 doses and then subcutaneously for the subsequent doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From baseline (Week 0) up to Week 48
- Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)Time frame: From baseline (Week 0) up to Week 48
- Number of Participants With Treatment-emergent Adverse Events of Special Interest (TEAESI)Time frame: From baseline (Week 0) up to Week 48
- Number of Participants With Treatment-emergent Abnormalities in Hematology Laboratory ParametersTime frame: From baseline (Week 0) up to Week 48
- Number of Participants With Treatment-emergent Abnormalities in Chemistry Laboratory ParametersTime frame: From baseline (Week 0) up to Week 48
- Number of Participants With TEAEs of InfectionsTime frame: From baseline (Week 0) up to Week 48
- Number of Participants With TEAEs of Injection-site ReactionsTime frame: From baseline (Week 0) up to Week 48
- Number of Participants With TEAEs Temporally Associated With InfusionTime frame: From baseline (Week 0) up to Week 48
- Number of Participants With TEAEs of Suicidal Ideation, Suicidal Behavior, or Self-Injurious Behavior Without Suicidal IntentTime frame: From baseline (Week 0) up to Week 48
- Number of Participants With Clinically Significant Treatment-emergent Abnormalities in Vital SignsTime frame: From baseline (Week 0) up to Week 48
- Number of Participants With Concomitant Medications for Crohn's DiseaseTime frame: From screening (Week -8) up to Week 48
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
KOKIKAI Tokatsu Tsujinaka Hospital
Abiko, Japan
Institute of Science Tokyo Hospital
Bunkyō City, Japan
Hitachi General Hospital
Hitachi, Japan
Asahikawa Medical University Hospital
Hokkaido, Japan
Ofuna Chuo Hospital
Kamakura, Japan
Kishiwada Tokushukai Hospital
Kishiwada, Japan
Kumamoto University Hospital
Kumamoto, Japan
Japanese Red Cross Kumamoto Hospital
Kumamoto, Japan
Kyorin University Hospital
Mitaka, Japan
Kenseikai Dongo Hospital
Nara, Japan
Hyogo Medical University Hospital
Nishinomiya Shi, Japan
Ishida Clinic of IBD and Gastroenterology
Ōita, Japan
Okayama University Hospital
Okayama, Japan
Saga University Hospital
Saga, Japan
Kitasato University Hospital
Sagamihara, Japan
Saitama Medical Center
Saitama, Japan
Sapporo Tokushukai Hospital
Sapporo, Japan
Sendai Kosei Hospital
Sendai Miyagi, Japan
Jichi Medical University Hospital
Shimotsuke, Japan
National Center for Global Health and Medicine
Shinjuku- Ku, Japan
Tokyo Women's Medical University Hospital
Shinjuku-ku, Japan
Tokyo Metropolitan Bokutoh Hospital
Sumida Ku, Japan
Osaka Medical and Pharmaceutical University Hospital
Takatsuki, Japan
Toyama Prefectural Central Hospital
Toyama, Japan
National Hospital Organization Toyohashi Medical Center
Toyohashi, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.